Monday, May 18, 2026

Cresco Labs: Analyst Q4 2020 Consensus Expectations

Cresco Labs (CSE: CL) announced that they will be reporting their fourth quarter and year-end financials pre-market on March 25th. Analysts have a consensus C$22.22 12-month price target on the company, via a total of 16 analysts, with four analysts having a strong buy rating and the other 11 have buy ratings and one analyst has a hold rating. The street high comes from Stifel-GMP with a C$36 price target, and the lowest target comes from Roth Capital with a C$17.50 price target.

Sixteen analysts have revenue estimates for the fourth quarter. The mean between all 16 is U$161.38 million; this number has been revised downwards from U$162.50 million at the start of the year. Needham & Co currently has the highest revenue estimate with U$167.8 million, while the lowest comes from Piper Sandler with a U$156.1 million estimate.

For the full year, the average revenue estimate between 16 analysts is currently U$475.52 million. This number has been revised downwards from U$475.52 million at the start of the year. The street high comes from Needham & Co with a U$481.70 full-year revenue estimate, while the lowest comes from Piper Sandler with a U$470 million estimate.

Onto EBITDA estimates, there are currently 14 analysts who have fourth-quarter EBITDA estimates. The mean is currently U$48.06 million, with this number roughly the same since the start of the year. Street high goes to Needham & Co with a U$52,14 million EBITDA estimate and the lowest being ATB Capital with a U$42.20 million estimate.

For the full year, the current EBITDA mean across 12 analysts is U$114.13 million. This number is roughly the same since the start of the year. Needham & Co currently has the highest full-year estimate at U$118.21 million and the lowest being Benchmark with a U$158 million estimate.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

First Majestic Q1 Earnings: A Bang Up Quarter

Copper’s Structural Shortage May Be Here to Stay | Colin Joudrie – Selkirk Copper

Why Barrick’s “Strong” Quarter Wasn’t So Strong | Q1 2026 Earnings

Recommended

Canada Confirms First Hantavirus Case Linked to MV Hondius Cruise Ship Outbreak

Altamira Gold Extends Maria Bonita Porphyry System Westward With 70.6 Metres At 0.51 g/t Hit

Related News

Stifel: WELL Health Is A “Unique Business Model Still In High Growth Phase”

Earlier this month, WELL Health Technologies (TSX: WELL) reported their second quarter financials, with quarterly...

Sunday, August 23, 2020, 04:05:00 PM

Canaccord Lowers Aurora Cannabis Price Target To $5 Following Q2 Earnings

On February 10th, Aurora Cannabis (TSX: ACB) reported its fiscal second quarter 2022 results. The...

Sunday, February 13, 2022, 05:16:00 PM

GFL Environmental: BMO Lifts Target To US$42 After Asset Divesture

At the start of the month, GFL Environmental Inc. (TSX: GFL) announced that they completed...

Friday, October 15, 2021, 11:34:00 AM

Microsoft: Earnings Estimates For Q1 2022

Microsoft (NASDAQ: MSFT) will be reporting its first quarter financial results on the 26th after...

Monday, October 25, 2021, 04:01:00 PM

Green Thumb: Analysts Call For $207 Million In Q2 Revenue

Green Thumb Industries (CSE: GTII) announced that they will be reporting their second quarter financials...

Monday, August 9, 2021, 03:36:00 PM